AU2003263834A1 - Mutations in nod2 are associated with fibrostenosing disease in patients with crohn's disease - Google Patents

Mutations in nod2 are associated with fibrostenosing disease in patients with crohn's disease

Info

Publication number
AU2003263834A1
AU2003263834A1 AU2003263834A AU2003263834A AU2003263834A1 AU 2003263834 A1 AU2003263834 A1 AU 2003263834A1 AU 2003263834 A AU2003263834 A AU 2003263834A AU 2003263834 A AU2003263834 A AU 2003263834A AU 2003263834 A1 AU2003263834 A1 AU 2003263834A1
Authority
AU
Australia
Prior art keywords
disease
crohn
fibrostenosing
nod2
fibrostenosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003263834A
Other languages
English (en)
Other versions
AU2003263834A8 (en
Inventor
Maria T. Abreu
Jerome I. Rotter
Kazuhito Sugimura
Stephan R. Targan
Kent D. Taylor
Huiying Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of AU2003263834A8 publication Critical patent/AU2003263834A8/xx
Publication of AU2003263834A1 publication Critical patent/AU2003263834A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2003263834A 2002-08-30 2003-07-30 Mutations in nod2 are associated with fibrostenosing disease in patients with crohn's disease Abandoned AU2003263834A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40739102P 2002-08-30 2002-08-30
US60/407,391 2002-08-30
US10/356,736 US20040053263A1 (en) 2002-08-30 2003-01-30 Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
US10/356,736 2003-01-30
PCT/US2003/023926 WO2004020968A2 (en) 2002-08-30 2003-07-30 Mutations in nod2 are associated with fibrostenosing disease in patients with crohn’s disease

Publications (2)

Publication Number Publication Date
AU2003263834A8 AU2003263834A8 (en) 2004-03-19
AU2003263834A1 true AU2003263834A1 (en) 2004-03-19

Family

ID=31981139

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003263834A Abandoned AU2003263834A1 (en) 2002-08-30 2003-07-30 Mutations in nod2 are associated with fibrostenosing disease in patients with crohn's disease

Country Status (7)

Country Link
US (2) US20040053263A1 (enExample)
EP (1) EP1556405B1 (enExample)
JP (2) JP4606877B2 (enExample)
AT (1) ATE462710T1 (enExample)
AU (1) AU2003263834A1 (enExample)
DE (1) DE60331941D1 (enExample)
WO (1) WO2004020968A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828132B2 (en) * 2001-03-01 2004-12-07 Ultra Biotech Limited Biological fertilizer compositions comprising garbage
US20040053263A1 (en) * 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
US7662569B2 (en) * 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
AU2004294526A1 (en) * 2003-12-03 2005-06-16 Glycominds, Ltd Method for diagnosing diseases based on levels of anti-glycan antibodies
US20060205022A1 (en) * 2003-12-03 2006-09-14 Nir Dotan Method for diagnosing and prognosing inflammatory bowel disease and crohn's disease
US7592150B2 (en) * 2003-12-03 2009-09-22 Glycominds, Ltd Method for diagnosing diseases based on levels of anti-glycan antibodies
DK1730315T3 (da) * 2004-03-27 2010-03-08 Klein Hanss Georg Polymorphismer i NOD2/Card15 gen
WO2005115135A2 (en) * 2004-04-09 2005-12-08 The Regents Of The University Of California Mouse model of crohn’s disease and a method to develop specific therapeutics
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US12110555B2 (en) 2004-12-08 2024-10-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
WO2008109782A2 (en) * 2007-03-06 2008-09-12 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US10544459B2 (en) * 2004-12-08 2020-01-28 Cedars-Sinai Medical Center Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease
WO2008101133A2 (en) * 2007-02-14 2008-08-21 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
WO2006063093A2 (en) * 2004-12-08 2006-06-15 Cedars-Sinai Medical Center Methods for diagnosis and treatment of crohn's disease
CA2658563A1 (en) * 2006-07-26 2008-01-31 Genizon Biosciences Inc. Crohn disease susceptibility gene
EP2102651A4 (en) * 2006-11-30 2010-11-17 Navigenics Inc GENERALYSIS SYSTEMS AND METHODS
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
WO2008137762A2 (en) * 2007-05-04 2008-11-13 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20110136255A1 (en) * 2007-11-30 2011-06-09 Nir Dotan Composition and method for prediction of complicated disease course in crohn's disease
WO2009143278A2 (en) * 2008-05-20 2009-11-26 Cedars-Sinai Medical Center Methods of diagnosing and characterizing cannabinoid signaling in crohn's disease
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
US20110229471A1 (en) * 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
CA2758531C (en) 2009-04-14 2018-11-13 Derren Barken Inflammatory bowel disease prognostics
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
WO2011088306A1 (en) * 2010-01-15 2011-07-21 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose crohn's disease
KR101934247B1 (ko) 2010-10-18 2019-01-02 네스텍 소시에테아노님 항-약물 항체 동종형의 확인 방법
DK2676137T3 (en) 2011-02-17 2015-01-19 Nestec Sa TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS
CA2830362A1 (en) * 2011-03-25 2012-10-04 Dermot P. Mcgovern Methods of diagnosing and treating intestinal granulomas and low bone density in inflammatory bowel disease
RU2013154566A (ru) 2011-05-10 2015-06-20 Нестек С.А. Способы анализа профиля активности болезни с целью проведения индивидуального лечения
WO2013059732A1 (en) 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
AU2014241162A1 (en) 2013-03-27 2015-10-22 Cedars-Sinai Medical Center Mitigation and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways
WO2014165825A2 (en) 2013-04-04 2014-10-09 President And Fellows Of Harvard College Therapeutic uses of genome editing with crispr/cas systems
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
BR112017020750A2 (pt) 2015-03-27 2018-06-26 Harvard College células t modificadas e métodos de produção e utilização das mesmas
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
WO2018195129A1 (en) 2017-04-17 2018-10-25 University Of Maryland, College Park Embryonic cell cultures and methods of using the same
WO2020139748A1 (en) * 2018-12-28 2020-07-02 Cedars-Sinai Medical Center Methods of treating inflammatory bowel diseases that target ripk2
AU2020383510A1 (en) * 2019-11-12 2022-05-12 Orchard Therapeutics (Europe) Limited Compositions and methods for treating or preventing Crohn's disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3157053B2 (ja) * 1992-09-16 2001-04-16 ティーディーケイ株式会社 Ｄｎａ作用物質の結合様式特定方法
DE69424700T2 (de) * 1993-03-10 2000-11-09 Cedars-Sinai Medical Center, Los Angeles Verfahren zum selektiven Nachweis von perinuklearen anti-neutrophilen cytoplasmischen Antikörpern bei ulzerativen Kolitis oder primärer sclerotischer Cholangitis
US5830675A (en) * 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US5874233A (en) * 1996-04-12 1999-02-23 Cedars-Sinai Medical Center Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis
WO1997038642A1 (en) * 1996-04-12 1997-10-23 Cedars-Sinai Medical Center Methods of determining the risk of pouchitis development
US5916748A (en) * 1996-04-12 1999-06-29 Cedars-Sinai Medical Center Method of diagnosing a clinical subtype of crohn's disease with features of ulcerative colitis
US6074835A (en) * 1996-04-12 2000-06-13 Regents Of The Univ. Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1
US5968741A (en) * 1997-04-11 1999-10-19 Cedars-Sinai Medical Center Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis
US6514700B1 (en) * 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
JP2001269196A (ja) * 2000-03-24 2001-10-02 Hamamatsu Photonics Kk 被検体核酸の定量方法、および被検体核酸の分子数の計数方法
US7138237B1 (en) * 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
US20040053263A1 (en) 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease

Also Published As

Publication number Publication date
WO2004020968A3 (en) 2004-08-26
US20070072180A1 (en) 2007-03-29
AU2003263834A8 (en) 2004-03-19
JP2011015686A (ja) 2011-01-27
ATE462710T1 (de) 2010-04-15
EP1556405A2 (en) 2005-07-27
DE60331941D1 (de) 2010-05-12
EP1556405B1 (en) 2010-03-31
US7790370B2 (en) 2010-09-07
US20040053263A1 (en) 2004-03-18
JP2006500016A (ja) 2006-01-05
JP4606877B2 (ja) 2011-01-05
WO2004020968A2 (en) 2004-03-11
EP1556405A4 (en) 2007-01-10

Similar Documents

Publication Publication Date Title
AU2003263834A1 (en) Mutations in nod2 are associated with fibrostenosing disease in patients with crohn's disease
WO2008137762A3 (en) Methods of diagnosis and treatment of crohn's disease
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
AU2002327308A1 (en) Methods for evaluating pathologic conditions using extracellular rna
AU3002699A (en) Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypesthereof, using microbial uc panca antigens
WO2000018954A3 (en) Use of pex in the treatment of metabolic bone diseases
ATE197964T1 (de) Bestimmung von mutationen im zusammenhang mit dem digeorge-syndrom
Aretz et al. Clinical Utility Gene Card for: Familial adenomatous polyposis (FAP) and attenuated FAP (AFAP)-update 2014
WO2004043223A3 (en) Compositions and methods for the diagnosis and treatment of sepsis
WO2004007770A3 (en) Method for diagnosis of intestinal-type gastric tumors
WO2006133287A3 (en) Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
WO2003020118A3 (en) Diagnosis and treatment of vascular disease
EP1676914A4 (en) TYPE OF PATHOLOGICAL LYMPHOMA AND DIAGNOSTIC EVALUATION METHOD
WO2003101177A3 (en) Diagnosing predisposition to fat deposition and therapeutic methods for reducing fat deposition and treatment of associated conditions
AU1153300A (en) Methods of diagnosing or prognosing alzheimer's disease
WO2002059611A3 (en) Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides
WO2008112990A3 (en) Methods of diagnosis and treatment of crohn's disease
AU2904197A (en) Diagnostic method and apparatus based on polymorphism in an IL-6 gene
WO2000033161A3 (en) Methods to reduce variance in treatment studies using genotyping
AU2003233292A8 (en) Protein c polymorphisms
WO2002053018A3 (en) Method of detecting polymorphisms associated with breast carcinoma in mhc genes
WO2003007801A3 (en) Diagnosis and treatment of vascular disease
FI990380A7 (fi) Diagnostinen ja seulontamenetelmä
DE60033646D1 (de) Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase